About Us

Dupage Medical Technology, Inc. (DMT), a research and biotechnology company, is located in an Industrial park affiliated with the University of Illinois at Chicago. The major focus of our company is to develop effective and safer drugs to treat cardiovascular diseases that involve thrombosis and inflammation. Drugs currently under development include MB2mP6 and M3mP6 that are innovative peptide drugs encapsulated in a unique lipid formulation to yield high loading peptide nanoparticles (HLPN). These HLPN allow efficient intracellular peptide delivery enabling in vivo therapeutic use of peptides targeting the intracellular compartment. MB2mP6 and M3mP6 have both anti-inflammatory and anti-thrombotic effects by targeting a newly described signaling pathway in platelets and leukocytes. Despite potent anti-thrombotic effects, these drugs do not cause bleeding. The initial targeted indications are for the treatment of sepsis, myocardial ischemia/reperfusion injury (MI/RI) or renal ischemia/reperfusion injury (IRI). We have completed successful proof-of-concept animal studies showing the effectiveness of the drugs for these indications. These drugs also have the potential to be effective in treating other thrombo-inflammatory diseases such as acute respiratory distress syndrome (ARDS), stroke, bacterial pneumonia, etc.

Additionally, we have the unique patent-pending technology for generating HLPN, which is likely to attract customers with interests in developing peptide-based drugs to license this technology.

New drug development in the company has been supported by contracts/grants from the National Heart, Lung and Blood Institute. With the significant progress made in preclinical pharmacology and toxicology testing, we plan to raise an additional $10 million in private investment to support additional preclinical pharmacology and toxicology studies for IND approval and phase I clinical trials.

The Team

Xiaoping Du, MD, PhD

Xiaoping Du received medical degree from Suzhou Medical College, China, and PhD degree from the University of Sydney, Australia. He is UIC Distinguished…

Aleksandra Stojanovic, MS

Aleksandra is Chief Operating Officer at DuPage Medical Technology (DMT). She joined the company in 2020. With her entrepreneurial…

Randal A. Skidgel, PhD

Randal joined DuPage Medical Technology (DMT) as Senior Scientific Officer in 2016. He brings to DMT extensive experience in research on peptide…

Yong-Jian Geng, MD, PhD

Dr. Yong-Jian Geng received his medical degree in 1982 from Suzhou Medical College, China, and doctoral degree of medical science in clinic…

Invest In Us

Call our team today to schedule a meeting.